To test whether glutamine affects cDC1-mediated vaccine efficacy, we adopted a DC transfer model for tumour therapy30 by pulsing splenic cDC1s with OVA and poly I:C in glutamine-sufficient or -deficient medium prior to injection into B16-OVA tumour-bearing mice. Here, MPPE1 is linked to neoplasm.